GNMK : Summary for GenMark Diagnostics, Inc. - Yahoo Finance

U.S. Markets closed

GenMark Diagnostics, Inc. (GNMK)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.14+0.12 (+0.92%)
At close: 4:00PM EDT

13.14 0.00 (0.03%)
After hours: 4:05PM EDT

People also watch
FLDMNVDQNSTGGHDXELGX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close13.02
Open13.00
Bid11.00 x 1400
Ask0.00 x
Day's Range12.84 - 13.21
52 Week Range4.66 - 13.43
Volume323,767
Avg. Volume268,970
Market Cap618.25M
Beta0.83
PE Ratio (TTM)-11.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
    Capital Cube16 days ago

    GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017

    Categories: Yahoo Finance Get free summary analysis GenMark Diagnostics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of GenMark Diagnostics, Inc. – QIAGEN NV, PerkinElmer, Inc., Luminex Corp and Hologic, Inc. (QGEN-US, PKI-US, LMNX-US and HOLX-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • Business Wire21 days ago

    GenMark Diagnostics to Present at Cowen and Company’s 37th Annual Health Care Conference

    GenMark Diagnostics, Inc. , a leading provider of automated, multiplex molecular diagnostic testing systems, will present at Cowen and Company’s 37th Annual Health Care Conference to be held at the Marriott Copley Place in Boston, Massachusetts on Wednesday, March 8, 2017.

  • Associated Press23 days ago

    GenMark Diagnostics reports 4Q loss

    The Carlsbad, California-based company said it had a loss of 27 cents per share. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...